Ipsen

IPN.PA Large Cap

Healthcare · Drug Manufacturers - Specialty & Generic

Updated: Apr 5, 2026, 17:43 UTC

€167.50

+1.45% today

52W: €87.95 – €167.80

52W Low: €87.95 Position: 99.6% 52W High: €167.80

🔗 Compare Brokers

Key Metrics

P/E Ratio

31.43x

Price-to-Earnings

Forward P/E

12.71x

Forward Price/Earnings

P/S Ratio

3.51x

Price-to-Sales

EV/EBITDA

9.91x

Enterprise Value/EBITDA

Div. Yield

84%

Annual dividend yield

Market Cap

$13.8B

Market Capitalization

Revenue Growth

9.3%

YoY Revenue Growth

Profit Margin

11.29%

Net profit margin

ROE

10.44%

Return on Equity

Beta

0.34

Market sensitivity

Short Interest

—

% of float sold short

Avg. Volume

103,454

Average daily volume

Valuation Analysis

Signal

Fair

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Buy

16 analysts

Avg. Price Target

€151.94

-9.29% upside

Target Range

€117.00 – €175.00

About the Company

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injection for the treatment of pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer; Tazverik, a chemotherapy-free EZH2a inhibitor that is in phase III clinical trial for the treatment of second line follicular lymphoma; Tovorafenib that is in phase III clinical trial to treat first line pediatric Low-Grade Gliomas and is In phase II clinical trial for the treatment of

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic Country: France Employees: 5,535 Exchange: PAR